Page last updated: 2024-12-06
n-carbobenzoxyglycylproline
Description
N-carbobenzoxyglycylproline: RN given refers to (L)-isomer; inhibits prolyl oligopeptidase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 439540 |
| CHEBI ID | 10096 |
| SCHEMBL ID | 2228388 |
| MeSH ID | M0135792 |
Synonyms (30)
| Synonym |
|---|
| n-[(benzyloxy)carbonyl]glycyl-l-proline |
| p0h , |
| n-carbobenzoxyglycylproline |
| z-gly-pro-oh |
| C01632 |
| 1160-54-9 |
| z-gly-pro |
| z-gly-pro, >=99.0% (tlc) |
| (2s)-1-[2-(phenylmethoxycarbonylamino)acetyl]pyrrolidine-2-carboxylic acid |
| A803553 |
| (2s)-1-(2-{[(benzyloxy)carbonyl]amino}acetyl)pyrrolidine-2-carboxylic acid |
| n-cbz-glycyl-l-proline |
| AKOS015919518 |
| ST51016177 , |
| z-glycyl-l-proline |
| CHEBI:10096 |
| SCHEMBL2228388 |
| (s)-1-(2-(((benzyloxy)carbonyl)amino)acetyl)pyrrolidine-2-carboxylic acid |
| Q-101548 |
| (2s)-1-[2-(benzyloxycarbonylamino)acetyl]pyrrolidine-2-carboxylic acid |
| mfcd00037341 |
| l-proline, n-[(phenylmethoxy)carbonyl]glycyl- |
| (s)-1-(2-(benzyloxycarbonylamino)acetyl)pyrrolidine-2-carboxylic acid |
| l-proline,n-[(phenylmethoxy)carbonyl]glycyl- |
| DS-15003 |
| Q27108580 |
| AMY41412 |
| DTXSID501292362 |
| CS-0147302 |
| z-l-glycyl-l-proline |
Drug Classes (1)
| Class | Description |
|---|
| peptide | Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |